PRTA Prothena Corporation plc Stock Quote

PRTA [NASD]

Index	-	P/E	-	EPS (ttm)	-0.24	Insider Own	5.49%	Shs Outstand	46.80M	Perf Week	0.29%
Market Cap	1.43B	Forward P/E	-	EPS next Y	-3.63	Insider Trans	-6.88%	Shs Float	44.29M	Perf Month	-3.60%
Income	-1.50M	PEG	-	EPS next Q	-0.58	Inst Own	99.50%	Short Float	5.94%	Perf Quarter	22.54%
Sales	142.80M	P/S	10.02	EPS this Y	149.60%	Inst Trans	-0.03%	Short Ratio	7.88	Perf Half Y	-15.81%
Book/sh	8.70	P/B	3.61	EPS next Y	-25.10%	ROA	-0.20%	Target Price	66.62	Perf Year	-46.23%
Cash/sh	11.16	P/C	2.81	EPS next 5Y	-0.60%	ROE	-0.30%	52W Range	21.06 - 79.75	Perf YTD	-36.50%
Dividend	-	P/FCF	87.74	EPS past 5Y	18.10%	ROI	14.40%	52W High	-61.40%	Beta	1.30
Dividend %	-	Quick Ratio	13.00	Sales past 5Y	185.60%	Gross Margin	-	52W Low	46.15%	ATR	1.74
Employees	82	Current Ratio	13.00	Sales Q/Q	-97.80%	Oper. Margin	-3.50%	RSI (14)	48.52	Volatility	4.79% 5.48%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-251.20%	Profit Margin	-1.00%	Rel Volume	0.43	Prev Close	31.37
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Aug 08 AMC	Payout	0.00%	Avg Volume	334.03K	Price	30.78
Recom	1.70	SMA20	-2.22%	SMA50	4.81%	SMA200	-15.00%	Volume	35,437	Change	-1.88%

Nov-19-21

Initiated

JMP Securities

Mkt Outperform

$77

Jun-18-21

Upgrade

BofA Securities

Underperform → Neutral

$12 → $49

Jun-08-21

Reiterated

Oppenheimer

Outperform

$45 → $54

May-26-21

Initiated

Citigroup

Buy

$39

Feb-26-21

Upgrade

RBC Capital Mkts

Sector Perform → Outperform

$14 → $28

Feb-12-21

Upgrade

Jefferies

Hold → Buy

$15 → $30

Feb-02-21

Upgrade

BTIG Research

Neutral → Buy

$29

Dec-07-20

Initiated

H.C. Wainwright

Buy

$22

Jul-09-20

Upgrade

Oppenheimer

Perform → Outperform

$16

Nov-19-19

Upgrade

Evercore ISI

In-line → Outperform

$14

May-21-18

Downgrade

Barclays

Equal Weight → Underweight

$14 → $12

Apr-23-18

Downgrade

Jefferies

Buy → Hold

Apr-05-18

Reiterated

Barclays

Overweight

$70 → $50

Nov-20-17

Downgrade

Wedbush

Outperform → Neutral

$75 → $55

Sep-29-17

Reiterated

BTIG Research

Buy

$80 → $77

Sep-15-17

Initiated

RBC Capital Mkts

Outperform

$87

Aug-17-17

Initiated

Evercore ISI

Outperform

$83

Jul-11-17

Initiated

Jefferies

Buy

Apr-12-17

Initiated

Piper Jaffray

Overweight

$69

Apr-12-17

Initiated

Cantor Fitzgerald

Overweight

$86

Aug-09-22 10:37AM	Prothena (PRTA) Q2 Earnings Miss, Pipeline Progress in Focus Zacks -8.27%
Aug-08-22 05:45PM	Prothena (PRTA) Reports Q2 Loss, Misses Revenue Estimates Zacks
04:05PM	Prothena Reports Second Quarter 2022 Financial Results and Business Highlights GlobeNewswire
Aug-07-22 10:27AM	Prothena (NASDAQ:PRTA) delivers shareholders strong 57% CAGR over 3 years, surging 6.6% in the last week alone Simply Wall St.
Aug-02-22 04:05PM	Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Aug-01-22 04:05PM	Prothena to Report Second Quarter 2022 Financial Results on August 8th GlobeNewswire
Jul-01-22 04:16PM	Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Jun-22-22 10:47AM	Prothena Corporation plc's (NASDAQ:PRTA) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock? Simply Wall St.
Jun-09-22 11:30AM	Why Is Epizyme (EPZM) Up 51.7% Since Last Earnings Report? Zacks
Jun-02-22 04:05PM	Prothena to Participate in Jefferies Healthcare Conference GlobeNewswire
May-08-22 08:02AM	These Analysts Just Made A Massive Downgrade To Their Prothena Corporation plc (NASDAQ:PRTA) EPS Forecasts Simply Wall St.
May-06-22 12:24PM	Prothena (PRTA) Q1 Earnings Beat, Pipeline Progress in Focus Zacks
May-05-22 06:35PM	Prothena (PRTA) Reports Q1 Loss, Tops Revenue Estimates Zacks -7.17%
04:05PM	Prothena Reports First Quarter 2022 Financial Results and Business Highlights GlobeNewswire
May-02-22 03:44PM	Why RBC Capital Sees 'Multiple High-Risk' On This Neurology-Focused Stock Benzinga +5.04%
Apr-28-22 04:05PM	Prothena to Report First Quarter 2022 Financial Results on May 5th GlobeNewswire +10.50%
Apr-26-22 08:30AM	Prothena Receives FDA Fast Track Designation for PRX012, a Next-Generation Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimers Disease GlobeNewswire -14.05%
Apr-21-22 10:13AM	Prothena (PRTA) Stock Gains 51% in a Year: What Lies Ahead? Zacks
Mar-29-22 11:44AM	Prothena (PRTA) IND Application Gets FDA Clearance for AD Zacks
Mar-28-22 08:30AM	Prothena Announces FDA Clearance of IND for PRX012, a Subcutaneous Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimers Disease GlobeNewswire
Mar-21-22 04:05PM	Prothena to Participate in Stifel 2022 Virtual CNS Days GlobeNewswire
Mar-16-22 09:20AM	Prothena Highlinghts New Preclinical Data For Alzheimer's, Parkinson's Vaccine Programs Benzinga +7.14%
05:30AM	Prothena Presents New Data for Alzheimers and Parkinsons Disease Programs at AD/PD 2022 GlobeNewswire
Feb-18-22 10:05AM	Prothena (PRTA) Q4 Earnings Beat, Pipeline Progress in Focus Zacks
Feb-17-22 05:45PM	Prothena (PRTA) Reports Q4 Loss, Tops Revenue Estimates Zacks -5.90%
04:05PM	Prothena Reports Fourth Quarter and Full Year 2021 Financial Results, and Provides Financial Guidance and Business Highlights GlobeNewswire
Feb-10-22 04:05PM	Prothena to Report Fourth Quarter and Full Year 2021 Financial Results and Host Webcast Conference Call on February 17, 2022 GlobeNewswire
Feb-03-22 05:38PM	Xcel Wealth Management, LLC Buys Affirm Holdings Inc, Bloomin Brands Inc, Skyworks Solutions ... GuruFocus.com
03:01PM	Will Prothena (PRTA) Report Negative Q4 Earnings? What You Should Know Zacks
02:36PM	10 Biotech Stocks to Buy According to Matthew Strobecks Birchview Capital Insider Monkey
Jan-28-22 01:38PM	Bellwether Advisors, LLC Buys Financial Select Sector SPDR, Consumer Discretionary Select ... GuruFocus.com
Jan-27-22 01:38PM	Hunter Perkins Capital Management, LLC Buys Canadian Pacific Railway, U.S. ... GuruFocus.com -6.76%
Jan-18-22 02:57PM	Top Biotech Stocks for Q1 2022 Investopedia -6.37%
Jan-10-22 11:02AM	Will Weakness in Prothena Corporation plc's (NASDAQ:PRTA) Stock Prove Temporary Given Strong Fundamentals? Simply Wall St.
Dec-23-21 08:09AM	5 Biotech Stocks That More Than Doubled This Year Zacks
Dec-12-21 03:55PM	Hedge Funds Are Crazy About Prothena Corporation plc (PRTA) Insider Monkey
Dec-07-21 01:51PM	7 Best Drug Stocks to Buy for 2022 Without Covid Catalysts InvestorPlace +12.03%
Dec-03-21 11:58AM	7 A-Rated Biotechs to Buy for the Long Run InvestorPlace -6.20%
Nov-29-21 04:05PM	Prothena to Participate in JMP Securities Hematology and Oncology Summit GlobeNewswire
Nov-25-21 08:25AM	While shareholders of Prothena (NASDAQ:PRTA) are in the black over 1 year, those who bought a week ago aren't so fortunate Simply Wall St.
Nov-22-21 10:38AM	Notable Prothena Corp Insider Trades $650K In Company Stock Benzinga
Nov-18-21 08:43AM	Cassava (SAVA) Down on Report of SEC Investigation Into AD Program Zacks
Nov-10-21 09:14AM	Were These Hedge Funds Right About Buying Prothena Corporation plc (PRTA)? Insider Monkey
Nov-05-21 08:59AM	Prothena (PRTA) Q3 Earnings Miss, Pipeline Progress in Focus Zacks
Nov-04-21 08:56PM	Prothena (PRTA) Q3 Earnings and Revenues Miss Estimates Zacks
04:05PM	Prothena Reports Third Quarter 2021 Financial Results and Business Highlights GlobeNewswire
11:16AM	Notable Prothena Corp Insider Trades $720K In Company Stock Benzinga
Nov-01-21 11:26AM	7 A-Rated Healthcare Stocks to Buy for the Long Haul InvestorPlace
Oct-28-21 04:05PM	Prothena to Report Third Quarter 2021 Financial Results on November 4th GlobeNewswire
11:40AM	VRTX vs. PRTA: Which Stock Is the Better Value Option? Zacks
Oct-27-21 03:03PM	Prothena (PRTA) to Report Q3 Results: Wall Street Expects Earnings Growth Zacks -10.39%
Oct-26-21 02:03PM	Do Hedge Funds Love Prothena Corporation plc (PRTA)? Insider Monkey
Oct-23-21 06:08AM	15 Biotech and Pharmaceutical Stocks to Buy According to Palo Alto Investors Insider Monkey
Oct-15-21 09:34AM	Prothena (PRTA) Riding High on Alzheimer's Disease Pipeline Zacks
Oct-12-21 11:40AM	VRTX vs. PRTA: Which Stock Should Value Investors Buy Now? Zacks -5.43%
09:10AM	Roche's (RHHBY) AD Drug Gets Breakthrough Therapy Status Zacks
Oct-11-21 01:06PM	Does This Valuation Of Prothena Corporation plc (NASDAQ:PRTA) Imply Investors Are Overpaying? Simply Wall St.
Oct-04-21 11:54AM	Notable Prothena Corp Insider Trades $830K In Company Stock Benzinga
Oct-01-21 04:30PM	Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
04:05PM	Prothena Announces Executive Appointments GlobeNewswire
Sep-23-21 11:40AM	VRTX vs. PRTA: Which Stock Should Value Investors Buy Now? Zacks
Sep-18-21 09:13AM	With Prothena Up Over 500% This Year, Is It Too Late to Get in? Motley Fool
Sep-09-21 12:00PM	Here's Why Prothena (PRTA) is a Great Momentum Stock to Buy Zacks
Sep-03-21 04:05PM	Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Sep-01-21 04:05PM	Prothena to Participate in Upcoming September Healthcare Conferences GlobeNewswire
11:30AM	AC Immune's (ACIU) Stock Up Despite Mixed Data From AD Study Zacks
Aug-25-21 04:46AM	Would-Be Buyers Should Wait for a Dip in Bullish Prothena TheStreet.com
Aug-11-21 08:02AM	Rainbows and Unicorns: Prothena Corporation plc (NASDAQ:PRTA) Analysts Just Became A Lot More Optimistic Simply Wall St.
Aug-09-21 01:32AM	Prothena Corporation plc Just Missed EPS By 34%: Here's What Analysts Think Will Happen Next Simply Wall St.
Aug-06-21 12:41PM	Prothena (PRTA) Q2 Earnings Top Estimates, Pipeline in Focus Zacks
Aug-05-21 05:25PM	Prothena (PRTA) Q2 Earnings Top Estimates Zacks
04:05PM	Prothena Reports Second Quarter 2021 Financial Results and Business Highlights GlobeNewswire
Aug-03-21 11:33AM	Ocugen (OCGN) to Report Q2 Earnings: What's in the Cards? Zacks
09:01AM	10 Stocks to Buy According to Neil Shahrestanis Ikarian Capital Insider Monkey
Jul-29-21 04:05PM	Prothena to Report Second Quarter 2021 Financial Results on August 5th GlobeNewswire -5.73%
03:05PM	Prothena (PRTA) Earnings Expected to Grow: What to Know Ahead of Q2 Release Zacks
Jul-26-21 03:27PM	Is Prothena Corporation plc (PRTA) A Good Stock To Buy? Insider Monkey
09:00AM	Prothena Presents New Data from Robust Alzheimers Portfolio at the Alzheimers Association International Conference 2021 GlobeNewswire
Jul-20-21 04:05PM	Prothena to Present Data from Two of its Alzheimers Disease Programs at the Alzheimers Association International Conference 2021 GlobeNewswire
Jul-17-21 07:37AM	Got $2,500? Check Out These 3 Alzheimer's Therapy Stocks Motley Fool
Jul-16-21 11:40AM	VRTX vs. PRTA: Which Stock Should Value Investors Buy Now? Zacks
07:18AM	Pharma Stock Roundup: NVO & LLY's Small Acquisitions, JNJ's Sunscreens Recall Zacks
Jul-14-21 03:21PM	Biotech Stock Roundup: BIIB & PRTA Provide Updates, CLDX Up on Positive Data & More Zacks
Jul-13-21 12:22PM	Prothena (PRTA) to Sell ATTR Amyloidosis Program to Novo Nordisk Zacks
Jul-12-21 12:45PM	Prothena sells ATTR amyloidosis portfolio to Novo Nordisk for up to $1.2 billion MarketWatch -8.19%
08:30AM	Novo Nordisk To Buy Prothena's ATTR Amyloidosis Program For Up To $1.2B Benzinga
07:08AM	Novo Nordisk to buy Prothena's heart drug in deal worth up to $1.2 billion Reuters
07:00AM	Novo Nordisk to buy Prothena's heart drug in deal worth up to $1.2 bln Reuters
07:00AM	Prothena and Novo Nordisk Announce Acquisition Agreement for Prothenas ATTR Amyloidosis Programme GlobeNewswire
03:52AM	Strength Seen in Prothena (PRTA): Can Its 7.3% Jump Turn into More Strength? Zacks
Jun-24-21 08:30AM	Prothena Announces Bristol Myers Squibb Opt-in of Anti-Tau PRX005 as the First Program from Global Neuroscience Research and Development Collaboration GlobeNewswire
Jun-18-21 04:53AM	Prothena Corp: Why Jeffries Analyst Almost Doubled His Price Target On the Stock? TipRanks
Jun-10-21 04:19PM	Why Biogen, Lilly, and Prothena Stocks Soared This Week Motley Fool +14.33%
02:18PM	Prothena to Participate in JMP Securities Life Sciences Conference on June 16 GlobeNewswire
11:30AM	Prothena (PRTA) Up 78.2% Since Last Earnings Report: Can It Continue? Zacks
Jun-09-21 04:58AM	Prothena (PRTA) Moves 5.9% Higher: Will This Strength Last? Zacks
May-20-21 04:05PM	Prothena Announces Appointment of Sanjiv Patel, MBBS, to its Board of Directors GlobeNewswire
May-12-21 03:32PM	Prothena (PRTA) Q1 Loss Wider Than Expected, Pipeline in Focus Zacks
May-11-21 04:05PM	Prothena Reports First Quarter 2021 Financial Results and Provides Updated Financial Guidance and R&D Update GlobeNewswire
06:57AM	Prothena Receives $60M Milestone Payment After Parkinson's Candidate Moves Forward In Mid-Stage Study With Dosing Benzinga

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kinney Gene G.	President and CEO	Aug 12	Option Exercise	6.41	20,284	130,020	33,077	Aug 12 09:30 PM
Kinney Gene G.	President and CEO	Aug 12	Sale	32.16	20,284	652,291	12,793	Aug 12 09:30 PM
Kinney Gene G.	President and CEO	Aug 11	Option Exercise	6.41	13,650	87,496	26,443	Aug 12 09:30 PM
Kinney Gene G.	President and CEO	Aug 11	Sale	32.16	13,650	438,931	12,793	Aug 12 09:30 PM
Kinney Gene G.	President and CEO	Aug 10	Option Exercise	6.41	991	6,352	13,784	Aug 12 09:30 PM
Kinney Gene G.	President and CEO	Aug 10	Sale	32.01	991	31,724	12,793	Aug 12 09:30 PM
Kinney Gene G.	President and CEO	Aug 05	Option Exercise	6.41	21,506	137,853	34,299	Aug 05 09:34 PM
Kinney Gene G.	President and CEO	Aug 05	Sale	32.83	21,506	706,063	12,793	Aug 05 09:34 PM
Kinney Gene G.	President and CEO	Aug 04	Option Exercise	6.41	20,954	134,315	33,747	Aug 05 09:34 PM
Kinney Gene G.	President and CEO	Aug 04	Sale	32.18	20,954	674,316	12,793	Aug 05 09:34 PM
Garren Hideki	Chief Medical Officer	Aug 01	Option Exercise	24.90	4,000	99,600	4,000	Aug 03 09:39 PM
Garren Hideki	Chief Medical Officer	Aug 01	Sale	30.52	4,000	122,080	0	Aug 03 09:39 PM
Kinney Gene G.	President and CEO	Jul 27	Option Exercise	6.41	376	2,410	13,169	Jul 29 09:30 PM
Kinney Gene G.	President and CEO	Jul 27	Sale	32.00	376	12,032	12,793	Jul 29 09:30 PM
Nguyen Tran	Chief Strategy Officer and CFO	Jul 22	Option Exercise	6.73	7,320	49,264	10,520	Jul 22 09:37 PM
Nguyen Tran	Chief Strategy Officer and CFO	Jul 22	Sale	32.55	7,320	238,254	3,200	Jul 22 09:37 PM
Nguyen Tran	Chief Strategy Officer and CFO	Jul 21	Option Exercise	6.73	20,560	138,369	23,760	Jul 22 09:37 PM
Nguyen Tran	Chief Strategy Officer and CFO	Jul 21	Sale	32.64	20,560	671,094	3,200	Jul 22 09:37 PM
Cooke Shane	Director	Jul 20	Option Exercise	6.41	15,000	96,150	15,000	Jul 22 09:33 PM
Nguyen Tran	Chief Strategy Officer and CFO	Jul 20	Option Exercise	6.73	42,120	283,468	45,320	Jul 22 09:37 PM
Nguyen Tran	Chief Strategy Officer and CFO	Jul 20	Sale	32.49	42,120	1,368,441	3,200	Jul 22 09:37 PM
Cooke Shane	Director	Jul 20	Sale	32.90	15,000	493,500	0	Jul 22 09:33 PM
Garren Hideki	Chief Medical Officer	Jul 06	Option Exercise	24.90	8,000	199,200	8,000	Jul 08 09:34 PM
Garren Hideki	Chief Medical Officer	Jul 06	Sale	30.00	8,000	240,000	0	Jul 08 09:34 PM
EcoR1 Capital, LLC	10% Owner	May 05	Buy	29.02	1,062,736	30,840,599	11,584,280	May 09 06:01 AM
EcoR1 Capital, LLC	10% Owner	May 05	Sale	29.02	1,062,736	30,840,599	11,584,280	May 09 06:01 AM
Cooke Shane	Director	Apr 11	Option Exercise	6.41	5,000	32,050	5,000	Apr 13 09:45 PM
Cooke Shane	Director	Apr 11	Sale	35.08	5,000	175,382	0	Apr 13 09:45 PM
COLLIER RICHARD T	Director	Apr 05	Option Exercise	6.41	5,000	32,050	6,219	Apr 07 09:47 PM
COLLIER RICHARD T	Director	Apr 05	Sale	39.41	5,000	197,027	1,219	Apr 07 09:47 PM
EcoR1 Capital, LLC	10% Owner	Jan 12	Buy	37.50	300,000	11,250,300	11,584,280	Jan 12 06:12 PM
Selkoe Dennis J.	Director	Jan 03	Option Exercise	9.23	5,000	46,150	7,845	Jan 05 09:02 PM
Selkoe Dennis J.	Director	Jan 03	Sale	47.45	5,000	237,233	2,845	Jan 05 09:02 PM
Walker Karin L	Chief Accounting Officer	Nov 23	Option Exercise	15.04	4,519	67,966	4,519	Nov 26 09:19 PM
Walker Karin L	Chief Accounting Officer	Nov 23	Sale	57.88	4,519	261,573	0	Nov 26 09:19 PM
Malecek Michael J	See Remarks	Nov 19	Option Exercise	10.27	10,000	102,700	10,000	Nov 19 09:32 PM
Malecek Michael J	See Remarks	Nov 19	Sale	55.00	10,000	550,000	0	Nov 19 09:32 PM
Karp Carol D.	Chief Regulatory Officer	Nov 01	Option Exercise	15.04	10,000	150,400	10,000	Nov 03 09:17 PM
Karp Carol D.	Chief Regulatory Officer	Nov 01	Sale	57.18	10,000	571,818	0	Nov 03 09:17 PM
Malecek Michael J	See Remarks	Oct 27	Option Exercise	10.27	10,000	102,700	10,000	Oct 29 05:00 PM
Malecek Michael J	See Remarks	Oct 27	Sale	58.52	10,000	585,250	0	Oct 29 05:00 PM
Walker Karin L	Chief Accounting Officer	Oct 20	Option Exercise	16.97	23,000	390,230	23,000	Oct 22 05:53 PM
Walker Karin L	Chief Accounting Officer	Oct 20	Sale	60.25	23,000	1,385,823	0	Oct 22 05:53 PM
Karp Carol D.	Chief Regulatory Officer	Oct 01	Option Exercise	15.04	10,000	150,400	10,000	Oct 01 08:46 PM
Selkoe Dennis J.	Director	Oct 01	Option Exercise	9.23	5,000	46,150	7,845	Oct 01 09:18 PM
Karp Carol D.	Chief Regulatory Officer	Oct 01	Sale	68.23	10,000	682,336	0	Oct 01 08:46 PM
Selkoe Dennis J.	Director	Oct 01	Sale	67.84	5,000	339,176	2,845	Oct 01 09:18 PM
Karp Carol D.	Chief Regulatory Officer	Sep 09	Option Exercise	15.04	10,000	150,400	10,000	Sep 10 05:06 PM
Karp Carol D.	Chief Regulatory Officer	Sep 09	Sale	71.98	10,000	719,847	0	Sep 10 05:06 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience